Kiora Pharmaceuticals

Home
United States
Encinitas, CA
Kiora Pharmaceuticals

Clinical stage biotech company focusing on novel therapeutics for the treatment of retinal diseases Kiora Pharmaceuticals, Inc.

(Kiora) is a clinical development-stage company focusing on novel therapeutics for the treatment of orphan retinal diseases with high unmet need. Publicly traded on the NASDAQ under KPRX, our mission is to help patients improve their ocular health and restore vision.

06/02/2026

Advancing new approaches to vision restoration.

KIO-301 is being explored as a potential option for people living with inherited retinal diseases, including conditions that lead to progressive vision loss such as retinitis pigmentosa.

At Kiora Pharmaceuticals, we are committed to developing therapies that address the underlying biology of retinal disease and help expand possibilities for vision restoration.

Learn more at https://kiorapharma.com/pipeline-science/kio-301/

05/27/2026

After being diagnosed with retinitis pigmentosa at 24 and becoming legally blind at 35, Lily Piccolo continued pursuing her passions, from teaching to competitive tandem cycling. Today, she uses her experiences to inspire others to keep pushing forward and pursuing what matters most.

Stories like Lily’s highlight the strength and resilience within the vision loss community. Learn more at kiorapharma.com

05/19/2026

KIO-104 is designed to selectively inhibit DHODH, a key enzyme involved in immune cell activation. By targeting this pathway, KIO-104 has the potential to address inflammatory retinal diseases while preserving essential cellular function in the eye.

At Kiora Pharmaceuticals, we are focused on developing therapies that address the underlying mechanisms of retinal disease and support long-term vision health.

Learn more at https://kiorapharma.com/pipeline-science/kio-104/

05/13/2026

For more than a decade, darkness was this participant’s reality. During a KIO-301 clinical trial, that reality changed — even if briefly. This firsthand experience highlights why Kiora continues to explore new approaches for inherited retinal disease through programs like KIO-301.

Learn more about KIO-301 at https://kiorapharma.com/pipeline-science/kio-301/

05/07/2026

We’re aiming to help the retina respond to light again. KIO-301 is a therapy in development for inherited retinal diseases that acts as a molecular photoswitch, designed to enable healthy retinal cells to detect light even when photoreceptors are no longer functional.

Discover how our research is approaching vision restoration at https://kiorapharma.com/pipeline-science/kio-301/

05/05/2026

Every name has a story. Ours begins with health, life, and vision in mind.

Kiora is inspired by kia ora, a Māori greeting wishing good health, and ora, meaning “eye” in Latin. Together, they reflect our purpose: improving health through better vision. This is the meaning behind Kiora.

Learn more at kiorapharma.com.

04/28/2026

The journey to restoring vision is built on rigorous science and expert collaboration.

Following our publication in Nature Medicine, Dr. Charles C. Wykoff underscores the significance of the ABACUS-1 trial results for KIO-301. Our goal has always been more than just clinical data—it's about "everyday vision benefit."

We are proud of these Phase 1 results showing safety and feasibility, and we are committed to the ongoing research necessary to bring this potentially life-changing therapy to those with advanced vision loss.

Read more at https://ir.kiorapharma.com/news-events/news-releases/detail/248/kioras-phase-1-abacus-study-of-kio-301-in-retinitis-pigmentosa-published-in-nature-medicine-phase-2-trial-underway

04/21/2026

We are pleased to share that our Phase 1 ABACUS-1 study of KIO-301 has been published in Nature Medicine. We are grateful for the opportunity to contribute to the peer-reviewed literature in this field.

As noted by Dr. Robert Casson, Principal Investigator of the study from the Royal Adelaide Hospital, the open-label, first-in-human trial met its primary safety endpoint, demonstrating short-term ocular safety and feasibility following intravitreal delivery, with no serious adverse events or dose-limiting toxicities reported. Exploratory findings — including light-induced cortical activity on fMRI and temporal improvements in functional vision measures in some participants — provide early clinical support for our molecular photoswitch approach.

We are deeply thankful to the patients and families who participated in the study, as well as the investigators, site teams, and our partners who made this milestone possible.

Read more at https://ir.kiorapharma.com/news-events/news-releases/detail/248/kioras-phase-1-abacus-study-of-kio-301-in-retinitis-pigmentosa-published-in-nature-medicine-phase-2-trial-underway

04/16/2026

Advancing new approaches to inflammatory retinal disease. KIO-104 is a locally delivered small molecule in development, designed to target inflammation at the source and offer a potential alternative to steroids or systemic anti-inflammatory drugs.

👉 Learn more about our pipeline at https://kiorapharma.com/pipeline-science/kio-104/

04/14/2026

Results from our Phase 1 ABACUS-1 clinical trial have been published in Nature Medicine. This peer-reviewed publication marks a significant milestone in our mission to restore vision for those living with inherited retinal diseases.

Our investigative therapy is a small molecule "photoswitch" designed to restore light sensitivity in patients with advanced vision loss. The study met its primary safety endpoints and provided early evidence of feasibility. The primary safety outcome was met with no serious ocular nor systemic adverse events reported over the study period, temporal improvements in light perception and functional vision were observed in some participants, and fMRI showed light-induced activity in the visual cortex, consistent with the therapy’s mechanism of action. Participant-reported quality-of-life scores showed improvements during the study period.

Read more at https://ir.kiorapharma.com/news-events/news-releases/detail/248/kioras-phase-1-abacus-study-of-kio-301-in-retinitis-pigmentosa-published-in-nature-medicine-phase-2-trial-underway

Address

332 Encinitas Boulevard, Suite 102
Encinitas, CA
92024

Website

http://kiorapharma.com/

Alerts

Be the first to know and let us send you an email when Kiora Pharmaceuticals posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Kiora Pharmaceuticals:

Shortcuts

Want your business to be the top-listed Health & Beauty Business in Encinitas?